Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas

Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively co...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 7; no. 11; pp. 5448 - 5456
Main Authors Li, Genpeng, Lei, Jianyong, Song, Linlin, Jiang, Ke, Wei, Tao, Li, Zhihui, Gong, Rixiang, Zhu, Jingqiang
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.11.2018
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text
ISSN2045-7634
2045-7634
DOI10.1002/cam4.1794

Cover

Loading…
Abstract Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. Results One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Conclusions Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. The radioiodine refractory differentiated thyroid carcinoma is associated with adverse prognosis and responsible for a large number of deaths. A multivariable prediction model was established, aiming to identify the potential patients, to optimize their management in the early stage.
AbstractList The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.OBJECTIVEThe purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.SUBJECTS AND METHODSData were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.RESULTSOne hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.CONCLUSIONSBased on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.
The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.
Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. Results One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Conclusions Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. The radioiodine refractory differentiated thyroid carcinoma is associated with adverse prognosis and responsible for a large number of deaths. A multivariable prediction model was established, aiming to identify the potential patients, to optimize their management in the early stage.
ObjectiveThe purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.Subjects and methodsData were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.ResultsOne hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.ConclusionsBased on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.
Abstract Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. Results One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Conclusions Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.
Author Zhu, Jingqiang
Gong, Rixiang
Lei, Jianyong
Wei, Tao
Song, Linlin
Li, Zhihui
Jiang, Ke
Li, Genpeng
AuthorAffiliation 1 Thyroid and Parathyroid Surgery Center West China Hospital of Sichuan University Chengdu China
AuthorAffiliation_xml – name: 1 Thyroid and Parathyroid Surgery Center West China Hospital of Sichuan University Chengdu China
Author_xml – sequence: 1
  givenname: Genpeng
  orcidid: 0000-0002-9771-221X
  surname: Li
  fullname: Li, Genpeng
  organization: West China Hospital of Sichuan University
– sequence: 2
  givenname: Jianyong
  orcidid: 0000-0002-8075-5416
  surname: Lei
  fullname: Lei, Jianyong
  organization: West China Hospital of Sichuan University
– sequence: 3
  givenname: Linlin
  surname: Song
  fullname: Song, Linlin
  organization: West China Hospital of Sichuan University
– sequence: 4
  givenname: Ke
  surname: Jiang
  fullname: Jiang, Ke
  organization: West China Hospital of Sichuan University
– sequence: 5
  givenname: Tao
  surname: Wei
  fullname: Wei, Tao
  email: weihospitaltao@yeah.net
  organization: West China Hospital of Sichuan University
– sequence: 6
  givenname: Zhihui
  surname: Li
  fullname: Li, Zhihui
  organization: West China Hospital of Sichuan University
– sequence: 7
  givenname: Rixiang
  surname: Gong
  fullname: Gong, Rixiang
  organization: West China Hospital of Sichuan University
– sequence: 8
  givenname: Jingqiang
  surname: Zhu
  fullname: Zhu, Jingqiang
  organization: West China Hospital of Sichuan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30264548$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAQgCNUREvpgRdAlrjAYVs7ceKEQ6XVip9KRUgIztbYnrReJXGwnaK98QbwjDwJTndb2gpyiZ1883nGM0-zvcENmGXPGT1mlOYnGnp-zETDH2UHOeXlQlQF37uz3s-OQljT9AiaV4I9yfaLtOAlrw-yn5_BWGedsQMSj60HHZ1PmxBI0M7jG7Ik_dRFewXeguqQjB6N1dG6gfTOYEda58noQnQjekhgEv2V_v7x61a7Ica2LXocooWIhsTLjXfWEA1e28H1EJ5lj1voAh7t3ofZ13dvv6w-LM4_vT9bLc8XuhQlX7CCKlqXnBdVKxqFIPIKmWpApSqhBQp5rWumhAYE0HVegRJFqWilmrLgqjjMzrZe42AtR2978BvpwMrrD85fSPDR6g5lrVHUlELVpsuExoAx6SxRYvKxVjXJdbp1jZPq0ehUnofunvT-n8Feygt3JaucV00hkuDVTuDdtwlDlL0NGrsOBnRTkDljXFDaNHVCXz5A127yQ7qqRBVlUzEqZurF3YxuU7npewJOtoD2LoTUIKlthLmnKUHbSUblPFxyHi45D1eKeP0g4kb6L3Zn_2473PwflKvlR34d8QftGeNu
CitedBy_id crossref_primary_10_3389_fendo_2022_768028
crossref_primary_10_3389_fendo_2021_691736
crossref_primary_10_3389_fendo_2022_930180
crossref_primary_10_2967_jnumed_118_222638
crossref_primary_10_1016_j_drup_2023_100939
crossref_primary_10_1016_j_jcte_2024_100373
crossref_primary_10_1016_j_heliyon_2020_e03450
crossref_primary_10_3389_fendo_2024_1433553
crossref_primary_10_1111_eci_13721
crossref_primary_10_1186_s13550_022_00917_8
crossref_primary_10_2147_JMDH_S403045
crossref_primary_10_3389_fendo_2023_1109439
crossref_primary_10_1097_MD_0000000000017876
crossref_primary_10_1007_s40618_024_02352_z
crossref_primary_10_1055_s_0044_1787731
crossref_primary_10_1007_s00259_022_05820_x
crossref_primary_10_1038_s41598_020_80015_8
crossref_primary_10_1097_RLU_0000000000005366
crossref_primary_10_2147_OTT_S308910
crossref_primary_10_1016_j_anndiagpath_2023_152243
crossref_primary_10_1210_clinem_dgae084
crossref_primary_10_3389_fonc_2020_549882
Cites_doi 10.1155/2010/921682
10.1158/1078-0432.CCR-08-0933
10.1097/CCO.0000000000000349
10.1002/cncr.23515
10.1089/thy.2009.0455
10.1056/NEJMoa1406470
10.1210/jc.2006-2707
10.1590/S0100-879X2010007500120
10.1001/archotol.133.10.1006
10.1677/erc.1.01119
10.1067/msy.2002.128690
10.1590/2359-3997000000245
10.1677/JOE-08-0333
10.1530/eje.0.1410443
10.1210/jc.2014-1171
10.1089/thy.2017.0422
10.1016/S0140-6736(14)60421-9
10.1089/thy.2015.0020
10.1507/endocrj.EJ14-0181
10.1038/sj.onc.1206602
10.1677/JOE-09-0436
ContentType Journal Article
Copyright 2018 The Authors. published by John Wiley & Sons Ltd.
2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2018 The Authors. published by John Wiley & Sons Ltd.
– notice: 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
– notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/cam4.1794
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: Proquest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate LI et al
EISSN 2045-7634
EndPage 5456
ExternalDocumentID oai_doaj_org_article_8ce7800a6f634a9dadd6e175e35b1fb9
PMC6246937
30264548
10_1002_cam4_1794
CAM41794
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  funderid: 81702646
– fundername: Postdoctoral Sustentation Fund of Sichuan University
  funderid: 2017SCU12035
– fundername: National Key R&D Program of China
  funderid: 2017YF0907504
– fundername: Sichuan Provience Science and Technology Project of China
  funderid: 2017SZ0139
– fundername: Sichuan University for youth fund
  funderid: 2017SCU11016
– fundername: Health and Family Planning Commission of Sichuan Province
  funderid: 17PJ398
– fundername: National Post‐Doctor Research Project
  funderid: 186717
– fundername: Postdoctoral Sustentation Fund of Sichuan University
  grantid: 2017SCU12035
– fundername: National Post‐Doctor Research Project
  grantid: 186717
– fundername: Sichuan University for youth fund
  grantid: 2017SCU11016
– fundername: Health and Family Planning Commission of Sichuan Province
  grantid: 17PJ398
– fundername: National Natural Science Foundation of China
  grantid: 81702646
– fundername: National Key R&D Program of China
  grantid: 2017YF0907504
– fundername: Sichuan Provience Science and Technology Project of China
  grantid: 2017SZ0139
GroupedDBID 0R~
1OC
24P
31~
53G
5VS
7X7
8-0
8-1
8FE
8FH
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACCMX
ACUHS
ACXQS
ADBBV
ADKYN
ADPDF
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
D-8
D-9
DIK
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
ITC
KQ8
LK8
M48
M7P
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
TEORI
TUS
UKHRP
WIN
AAYXX
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
PQGLB
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c5754-130b0854436f79bea726e1b9ab007afa0a28c81b7caeaac826ab735b06b9534b3
IEDL.DBID M48
ISSN 2045-7634
IngestDate Wed Aug 27 01:27:42 EDT 2025
Thu Aug 21 18:27:07 EDT 2025
Fri Sep 05 06:12:46 EDT 2025
Wed Aug 13 06:06:16 EDT 2025
Mon Jul 21 06:06:11 EDT 2025
Tue Jul 01 00:47:32 EDT 2025
Thu Apr 24 23:04:37 EDT 2025
Wed Jan 22 16:22:41 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords differentiated thyroid carcinoma
risk factors
radioiodine refractoriness
scoring system
Language English
License Attribution
2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5754-130b0854436f79bea726e1b9ab007afa0a28c81b7caeaac826ab735b06b9534b3
Notes Funding information
This study was supported by grants from National Key R&D Program of China (2017YF0907504), National Natural Science Foundation (81702646), National Post‐Doctor Research Project (186717), Sichuan Province Science and Technology Project of China (2017SZ0139), Sichuan University for youth fund (2017SCU11016), Health and Family Planning Commission of Sichuan Province (17PJ398), and Postdoctoral Sustentation Fund of Sichuan University (2017SCU12035).
Genpeng Li and Jianyong Lei contributed equally to the present work and each is considered first author.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8075-5416
0000-0002-9771-221X
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1794
PMID 30264548
PQID 2135961078
PQPubID 2032540
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_8ce7800a6f634a9dadd6e175e35b1fb9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6246937
proquest_miscellaneous_2114700998
proquest_journals_2135961078
pubmed_primary_30264548
crossref_citationtrail_10_1002_cam4_1794
crossref_primary_10_1002_cam4_1794
wiley_primary_10_1002_cam4_1794_CAM41794
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2018
PublicationDateYYYYMMDD 2018-11-01
PublicationDate_xml – month: 11
  year: 2018
  text: November 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bognor Regis
– name: Hoboken
PublicationTitle Cancer medicine (Malden, MA)
PublicationTitleAlternate Cancer Med
PublicationYear 2018
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2015; 56
2017; 61
2018; 28
2010; 2010
2010; 206
2006; 13
2002; 132
2007; 92
1999; 141
2017; 29
2012; 37
2014; 61
2015; 372
2010; 20
2013; 2013
2015; 133
2007; 133
2011; 44
2008; 113
2008; 199
2016; 26
2014; 384
2009; 15
2014; 99
2010; 9
2003; 22
Rose J (e_1_2_6_16_1) 2013; 2013
e_1_2_6_10_1
Dadu R (e_1_2_6_15_1) 2012; 37
Siegel RL (e_1_2_6_2_1) 2015; 56
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_14_1
Wassermann J (e_1_2_6_18_1) 2015; 133
e_1_2_6_11_1
e_1_2_6_12_1
e_1_2_6_17_1
e_1_2_6_21_1
e_1_2_6_20_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
Capdevila J (e_1_2_6_5_1) 2010; 9
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_22_1
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – volume: 15
  start-page: 485
  issue: 2
  year: 2009
  article-title: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma
  publication-title: Clin Cancer Res
– volume: 384
  start-page: 319
  issue: 9940
  year: 2014
  article-title: Sorafenib in radioactive iodine‐refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double‐blind, phase 3 trial
  publication-title: Lancet
– volume: 20
  start-page: 1235
  issue: 11
  year: 2010
  end-page: 1245
  article-title: The effectiveness of radioactive iodine for treatment of low‐risk thyroid cancer: a systematic analysis of the peer‐reviewed literature from 1966 to April 2008
  publication-title: Thyroid
– volume: 99
  start-page: 1368
  issue: 7
  year: 2014
  end-page: 1375
  article-title: mTOR Inhibition promotes TTF1‐dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines
  publication-title: J Clin Endocrinol Metab
– volume: 44
  start-page: 73
  issue: 1
  year: 2011
  end-page: 77
  article-title: Follow‐up of patients treated with retinoic acid for the control of radioiodine non‐responsive advanced thyroid carcinoma
  publication-title: Braz J Med Biol Res
– volume: 26
  start-page: 1
  issue: 1
  year: 2016
  article-title: 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer
  publication-title: Thyroid
– volume: 29
  start-page: 151
  issue: 2
  year: 2017
  article-title: Treatment and surveillance of advanced, metastatic iodine‐resistant differentiated thyroid cancer
  publication-title: Curr Opin Oncol
– volume: 22
  start-page: 4406
  issue: 28
  year: 2003
  end-page: 4412
  article-title: RET/PTC‐induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC‐RAS‐MAP kinase
  publication-title: Oncogene
– volume: 13
  start-page: 257
  issue: 1
  year: 2006
  end-page: 269
  article-title: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I‐ targeting to the membrane
  publication-title: Endocr Relat Cancer
– volume: 2010
  start-page: 921682
  year: 2010
  article-title: New targeted molecular therapies for dedifferentiated thyroid cancer
  publication-title: J Oncol
– volume: 199
  start-page: 243
  issue: 2
  year: 2008
  end-page: 252
  article-title: Phosphoinositide‐3‐kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells
  publication-title: J Endocrinol
– volume: 132
  start-page: 984
  issue: 6
  year: 2002
  end-page: 990
  article-title: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor
  publication-title: Surgery
– volume: 372
  start-page: 621
  issue: 7
  year: 2015
  end-page: 630
  article-title: Lenvatinib versus placebo in radioiodine‐refractory thyroid cancer
  publication-title: N Engl J Med
– volume: 113
  start-page: 48
  issue: 1
  year: 2008
  end-page: 56
  article-title: Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma
  publication-title: Cancer
– volume: 141
  start-page: 443
  issue: 5
  year: 1999
  end-page: 457
  article-title: Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism
  publication-title: Eur J Endocrinol
– volume: 61
  start-page: 821
  issue: 8
  year: 2014
  end-page: 824
  article-title: Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy
  publication-title: Endocr J
– volume: 28
  start-page: 301
  issue: 3
  year: 2018
  end-page: 310
  article-title: A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence
  publication-title: Thyroid
– volume: 56
  start-page: 106
  issue: 2
  year: 2015
  article-title: Cancer statistics, 2016
  publication-title: CA Cancer J Clin
– volume: 37
  start-page: 335
  issue: 4
  year: 2012
  end-page: 356
  article-title: Optimizing therapy for radioactive iodine‐refractory differentiated thyroid cancer: Current state of the art and future directions
  publication-title: Minerva Endocrinol
– volume: 9
  start-page: 153
  issue: 45
  year: 2010
  end-page: 162
  article-title: New approaches in the management of radioiodine‐refractory thyroid cancer: the molecular targeted therapy era
  publication-title: Discov Med
– volume: 206
  start-page: 113
  issue: 1
  year: 2010
  article-title: MTOR downregulates iodide uptake in thyrocytes
  publication-title: J Endocrinol
– volume: 133
  start-page: 1006
  issue: 10
  year: 2007
  article-title: Methylation status of genes in papillary thyroid carcinoma
  publication-title: Arch Otolaryngol Head Neck Surg
– volume: 2013
  start-page: 317487
  issue: 10
  year: 2013
  article-title: Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma
  publication-title: Int J Endocrinol
– volume: 92
  start-page: 2840
  issue: 7
  year: 2007
  end-page: 2843
  article-title: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism
  publication-title: J Clin Endocrinol Metab
– volume: 133
  start-page: P95
  issue: 2
  year: 2015
  end-page: P95
  article-title: Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas
  publication-title: Oncologist
– volume: 61
  start-page: 81
  issue: 1
  year: 2017
  article-title: Radioactive iodine‐refractory differentiated thyroid cancer: an uncommon but challenging situation
  publication-title: Arch Endocrinol Metab
– ident: e_1_2_6_6_1
  doi: 10.1155/2010/921682
– ident: e_1_2_6_9_1
  doi: 10.1158/1078-0432.CCR-08-0933
– volume: 56
  start-page: 106
  issue: 2
  year: 2015
  ident: e_1_2_6_2_1
  article-title: Cancer statistics, 2016
  publication-title: CA Cancer J Clin
– ident: e_1_2_6_3_1
  doi: 10.1097/CCO.0000000000000349
– ident: e_1_2_6_26_1
  doi: 10.1002/cncr.23515
– ident: e_1_2_6_13_1
  doi: 10.1089/thy.2009.0455
– ident: e_1_2_6_24_1
  doi: 10.1056/NEJMoa1406470
– ident: e_1_2_6_7_1
  doi: 10.1210/jc.2006-2707
– ident: e_1_2_6_4_1
  doi: 10.1590/S0100-879X2010007500120
– ident: e_1_2_6_22_1
  doi: 10.1001/archotol.133.10.1006
– ident: e_1_2_6_8_1
  doi: 10.1677/erc.1.01119
– ident: e_1_2_6_23_1
  doi: 10.1067/msy.2002.128690
– ident: e_1_2_6_14_1
  doi: 10.1590/2359-3997000000245
– volume: 9
  start-page: 153
  issue: 45
  year: 2010
  ident: e_1_2_6_5_1
  article-title: New approaches in the management of radioiodine‐refractory thyroid cancer: the molecular targeted therapy era
  publication-title: Discov Med
– ident: e_1_2_6_10_1
  doi: 10.1677/JOE-08-0333
– ident: e_1_2_6_19_1
  doi: 10.1530/eje.0.1410443
– ident: e_1_2_6_11_1
  doi: 10.1210/jc.2014-1171
– ident: e_1_2_6_27_1
  doi: 10.1089/thy.2017.0422
– ident: e_1_2_6_25_1
  doi: 10.1016/S0140-6736(14)60421-9
– volume: 2013
  start-page: 317487
  issue: 10
  year: 2013
  ident: e_1_2_6_16_1
  article-title: Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma
  publication-title: Int J Endocrinol
– ident: e_1_2_6_12_1
  doi: 10.1089/thy.2015.0020
– ident: e_1_2_6_17_1
  doi: 10.1507/endocrj.EJ14-0181
– volume: 133
  start-page: P95
  issue: 2
  year: 2015
  ident: e_1_2_6_18_1
  article-title: Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas
  publication-title: Oncologist
– ident: e_1_2_6_20_1
  doi: 10.1038/sj.onc.1206602
– volume: 37
  start-page: 335
  issue: 4
  year: 2012
  ident: e_1_2_6_15_1
  article-title: Optimizing therapy for radioactive iodine‐refractory differentiated thyroid cancer: Current state of the art and future directions
  publication-title: Minerva Endocrinol
– ident: e_1_2_6_21_1
  doi: 10.1677/JOE-09-0436
SSID ssj0000702671
Score 2.2460523
Snippet Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid...
The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC)...
ObjectiveThe purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma...
Abstract Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5448
SubjectTerms Clinical Cancer Research
differentiated thyroid carcinoma
Female
Humans
Iodine Radioisotopes - therapeutic use
Lymph nodes
Lymphatic system
Male
Metastases
Metastasis
Middle Aged
Models, Statistical
Original Research
Patients
Postoperative Period
Prediction models
Radiation Tolerance
radioiodine refractoriness
Radiopharmaceuticals - therapeutic use
Risk factors
scoring system
Smoking
Surgery
Survival Analysis
Thyroid cancer
Thyroid carcinoma
Thyroid Neoplasms - radiotherapy
Thyroid Neoplasms - surgery
Thyroidectomy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4puUggziwCU0iR1_cFsqqgppOSAq9WaNHUesBMkqbZG48Q_gN_JLmHGyYVcUceG6mc16Z95knpXxG8aeKxuVkRByaGyRSxshN9CqXAXRSI0EPZR0OHn5Tp2cyrdn9dnWqC_qCRvlgUfHHZoQNZIaUK0SEmyD-agi1rwoal-2Ph3dw5q3tZlKz2BNk5XKjZRQUR0G-CxfEvp2ClDS6b-KXP7ZI7nNXVPxOb7Fbk6skS_G1d5m12J3h11fTu_F77Lv76FZ9aseC1Hk-JNDmqKTOtr5OQlVvuILnnoHv-DemE5L8fVA36aw8DQNhyN75WuS2VjHUQ2cD79v-vPbj_m2X_lmqgo-HZCwcoz10K8aHmguUUcNR_fY6fGbD0cn-TRqIQ_I12SOlcwj-ZJSqFZbH0FX6GVvAbNSQwsFVCYgw9UBIkDAPQl4jREolLe1kF7cZ3td38WHjItW60YEbWtvZYzBFL4VWnhfGmO9Vhl7sfG_C5MOOY3D-ORGBeXKUagchSpjz2bT9Si-cZXRawribEB62ekDRJGbUOT-haKMHWwg4KYkPndVKWqL9FKbjD2dL2P60TsV6GJ_STal1ESz0ebBiJh5JQIxKHFHmDG9g6Wdpe5e6VYfk8S3qqRC4oi-Sqj7-793R4slDZGT-__DDY_YDSSEZjxrecD2LobL-BhJ14V_kvLrF0n1MXQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiDeBggziwCU0iR0_uKBt1apC2gpVVOotsh0HVoIkZFskfgT_mRnHSVlRuG4m2Tjz-myPvyHktdBeKG5camqdpVx7kyrTiFQ4VnMJAN3leDh5dSKOz_iH8_I8LrhtYlnlFBNDoK47h2vke0XOSg25Xqr3_fcUu0bh7mpsoXGT7EAIVuWC7Owfnnw8nVdZwKALIfOJUigr9pz5xt-iFW4losDXfx3I_LtW8k8MG5LQ0V1yJ6JHuhzVfY_c8O19cmsV98cfkF-npl536w4Skqfwl0PophMq2-kGCSvf0SUNNYQ_YI6Mp6ZoP-DdqB4auuJQQLG0R7qN3o-s4HS4emg6P_QnnXqrQIwA2EpB40O3rqnD7kQtlh09JGdHh58OjtPYcCF1gNp4CvnMAgTjnIlGauuNLITPrTbgm9I0JjOFcoBzpTPeGAczE2MlK20mrC4Zt-wRWbRd658Qyhopa-akLq3m3juV2YZJZm2ulLZSJOTN9PUrF9nIsSnG12rkUS4qVFSFikrIq1m0Hyk4rhPaRxXOAsiaHX7ohs9VdMJKOS8BIBvRCMaNriG2w_hk6WEMeWN1QnYnA6iiK2-qK8NLyMv5Mjgh7qyY1neXKJNziWAbZB6P9jK_CQML5DAvTIjcsqStV92-0q6_BKJvUXAB8BG-VbC5f4--OliusJUcf_r_ETwjtwHwqfEs5S5ZXAyX_jmAqgv7InrOb0wRJ6o
  priority: 102
  providerName: ProQuest
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZKkRAXxD-BggziwCU0iR07htNSUVVIixCiUm_W2HFgJUhW2RaJG28Az8iTMOP8lBVF4hpPEjszY3_jeL5h7KkyQVUSfAq1yVJpAqQVNCpVXtRSI0D3OSUnL9-qo2P55qQ82WEvp1yYgR9i3nAjz4jzNTk4uM3-OWmohy_yOZnTJXaZUmupfEEh380bLGjLhYoBFzGup-hHcmIWyor9-e6t9SjS9l-ENf8-MvknlI1r0eF1dm0EkXwxaP0G2wntTXZlOf4mv8V-vId61a06XJcCx1f2sahOPODON8Rb-YIveDxK-BVDZUqe4uue7iYt8VgchyOY5Wti3ViHgRyc9-cP_fX95_zYb3wqsoKTBeJXjqrvu1XNPZUpaun80W12fPj6w8FROlZeSD3CN5niwuYQi0kpVKONC6ALFXJnAJ1UQwMZFJVHwKs9BACPIQo4LUqXKWdKIZ24w3bbrg33GBeN1rXw2pTOyBB8lblGaOFcXlXGaZWwZ9P3t36kJafqGJ_tQKhcWFKVJVUl7Mksuh64OC4SekVKnAWIPjte6PqPdvRGW_mgESmDatAqwNQ4yeP4dBlwDHnjTML2JhOwo09vbJGL0iDa1FXCHs_N6I30iwXa0J2RTC41oW6UuTtYzNwTgfYoMUBMmN6ypa2ubre0q0-R8VsVUiGOxG8Vre7fo7cHiyXVlJP3_1_0AbuKKLAaEiz32O5pfxYeItI6dY-iR_0G_V0p3A
  priority: 102
  providerName: Wiley-Blackwell
Title Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1794
https://www.ncbi.nlm.nih.gov/pubmed/30264548
https://www.proquest.com/docview/2135961078
https://www.proquest.com/docview/2114700998
https://pubmed.ncbi.nlm.nih.gov/PMC6246937
https://doaj.org/article/8ce7800a6f634a9dadd6e175e35b1fb9
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB31Q0JcEN8slJVBHLikbGLHjpEQ2lYtFdJWVcVKe4tsx4GVSrKkLaI3_gH8Rn4JM06ydMUicclhM8nGnhn7TWK_B_BCai8zYVxkCj2KhPYmykwpI-l4IRQCdBfT5uTJsTyaivezdLYBvcZm14Hna0s70pOaNme7375cvcWEf9MRiL5y5rPYpcDahG2ckCQF96RD-WFAViSzRKUXca9HmFGi5xi6fvXKzBQI_Nehzr8XT14HtWFWOrwNtzo4ycat_-_Ahq_uwo1J98H8Hvw4NcW8ntc4Q3mGf9kEeZ2w1J2dE4PlazZmYVHhVyyaaRsVWzR0NfmLBZkchrCWLYh_Y-FbmnDW_Lnpr-8_l7e9Yr3cCg4biGQZBkFTzwvmSLCoopVI92F6ePBh_yjqNBgih0BORDjFWURlQnBZKm29UYn0sdUG01WZ0oxMkjmEvsoZb4zDYsVYxVM7klanXFj-ALaquvKPgPFSqYI7pVOrhfcuG9mSK25tnGXaKjmAl33_564jKCedjLO8pVZOcnJVTq4awPOl6aJl5VhntEdOXBoQkXb4oW4-5l1e5pnzCjGzkSVGhdEFDvfYPpV6bENcWj2AnT4E8j448yTmqUbcqbIBPFuexrykjy2m8vUl2cRCEf5Gm4dtxCyfhGM8CiwVB6BWYmnlUVfPVPNPgftbJkIiosS-ClH379bn--MJqcuJx__TV0_gJiLBrN1kuQNbF82lf4po68IOYTMRJ3hUMzWE7b2D45PTYXhzgcd3s3gYcu03fVMy1A
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKKwEXxD-BAgaBxCVtEjt2jITQtrTa0u4KVa3UW7Adp10JkpBtQX0IXoVnZCZ_ZUXh1utm4o0z38x8jsczhLwSyomEa-vrTAU-V077ic6FLyzLuASCbkM8nDyZivEh_3gUHy2RX_1ZGEyr7H1i46iz0uI38vUoZLGCWC-T99U3H7tG4e5q30KjhcWuO_8BS7b5u50PoN_XUbS9dbA59ruuAr4FasJ9cNoGeAbnTORSGadlJFxolAYASp3rQEeJBTInrXZaW6Df2kgWm0AYFTNuGIx7jawAzVBgRSsbW9NP-8NXHTCgSMiwL2EUROtWf-VriPqFwNf0B7iM1P6dm_knZ26C3vZtcqtjq3TUwusOWXLFXXJ90u3H3yM_93U2K2clBEBH4S_rpntPk0lP51gg8y0d0SZn8TusyfGUFq1qvBvhQJsuPBRYM62wvEfl2irktL4Y1B8GPad9LxfwSUCTKSCsLmcZtdgNqcA0p_vk8EpU8YAsF2XhHhHKcikzZqWKjeLO2SQwOZPMmDBJlJHCI2_6t5_arvo5NuH4krZ1m6MUFZWiojzychCt2pIflwltoAoHAazS3fxQ1sdpZ_RpYp0EQq5FLhjXKoNYAvOTsYM5hLlRHlntAZB2rmOeXgDdIy-Gy2D0uJOjC1eeoUzIJZJ7kHnY4mV4EgYI5LAO9YhcQNLCoy5eKWYnTWFxEXEBdBXeVYO5f88-3RxNsHUdf_z_GTwnN8YHk710b2e6-4TcBLKZtOc4V8nyaX3mngKhOzXPOiui5PNVG-5vsh1kaQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELXKVqp4QdxJKWAQSLyETWLHjpEQ2l5WLWVXVUWlvqW248BKJVmyLagfwQ_xdczkVlYU3vq6mXjjzJmZ43g8Q8hLoZxIuLa-zlTgc-W0n-hc-MKyjEsg6DbEw8mTqdg94h-O4-MV8qs7C4NplZ1PrB11Vlr8Rj6MQhYriPUyGeZtWsTB9vj9_JuPHaRwp7Vrp9FAZN9d_IDl2-Ld3jbo-lUUjXc-be36bYcB3wJN4T44cAOcg3MmcqmM0zISLjRKAxilznWgo8QCsZNWO60tUHFtJItNIIyKGTcMxr1BViVExWRAVjd3pgeH_RceMKZIyLArZxREQ6u_8jdoAUtBsO4VcBXB_TtP80_-XAfA8W1yq2WudNRA7Q5ZccVdsjZp9-bvkZ-HOpuVsxKCoaPwl1XdyafOqqcLLJb5lo5onb_4HdbneGKLziu8G6FB6448FBg0nWOpj7lrKpLT6nJQvx_0gnZ9XcA_AWWmgLaqnGXUYmekAlOe7pOja1HFAzIoysI9IpTlUmbMShUbxZ2zSWByJpkxYZIoI4VHXndvP7VtJXRsyHGaNjWcoxQVlaKiPPKiF5035T-uEtpEFfYCWLG7_qGsPqetA0gT6ySQcy1ywbhWGcQVmJ-MHcwhzI3yyEYHgLR1I4v0EvQeed5fBgeAuzq6cOU5yoRcItEHmYcNXvonYYBADmtSj8glJC096vKVYvalLjIuIi6AusK7qjH379mnW6MJtrHj6_-fwTOyBgabftyb7j8mN4F3Js2Rzg0yOKvO3RPgdmfmaWtElJxct93-Bt6IaJU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radioiodine+refractoriness+score%3A+A+multivariable+prediction+model+for+postoperative+radioiodine%E2%80%90refractory+differentiated+thyroid+carcinomas&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Li%2C+Genpeng&rft.au=Lei%2C+Jianyong&rft.au=Song%2C+Linlin&rft.au=Jiang%2C+Ke&rft.date=2018-11-01&rft.issn=2045-7634&rft.eissn=2045-7634&rft.volume=7&rft.issue=11&rft.spage=5448&rft.epage=5456&rft_id=info:doi/10.1002%2Fcam4.1794&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cam4_1794
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon